GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global G-Protein Coupled Receptors Market, By Product (Cell Lines, Detection Kits, Cell Culture Reagents, Ligands), By Assay Type (cAMP Functional Assays, Calcium Functional Assays, β-Arrestin Functional Assays, Radioligand Binding & GTPγS Functional Assays, Internalization Assays, Trafficking Assays, Other Assays), By Application (Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Other Applications), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global G-Protein Coupled Receptors Market- Recent Developments

Key Developments

On June 15, 2023, Confo Therapeutics, one of the leader in discovery of medicines targeting G-protein coupled receptors (GPCRs) announced that it has entered into a research collaboration with AbCellera, one of the biotechnology company for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
In January 2022, Sosei Group Corporation, a biopharmaceutical company that develops drugs by using a proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform and Verily, an alphabet precision health company announced that they have entered into a strategic research collaboration. The research agreement brings together the complementary capabilities of Verily's immune profiling and Sosei Heptares' G-protein-coupled receptors (GPCR) structure-based drug design.

Business Development Activities by the Market Players

In April 2022, Ono Pharmaceutical Co., Ltd., one of the largest pharmaceutical companies in Japan embarked on a collaborative endeavor with Domain Therapeutics, a biopharmaceutical company focused on GPCR in immuno-oncology and the Universite de Montreal for the purpose of identifying cutting-edge small molecules that modulate G-Protein coupled receptors (GPCRs), with a particular focus on a metabolic disease.
In January 2022, Septerna, Inc., a biotechnology firm, successfully completed a fundraising event, securing a series A investment totaling US$ 100 Mn. The capital injection is aimed at propelling the development of GPCR-targeted therapeutics through the utilization of their proprietary native complex platform. This advancement is expected to address the historic difficulties that are associated with harnessing the substantial but largely unrealized therapeutic potential of GPCR targets across diverse disease spectrums.